EYPT (EyePoint, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by EYPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | George Elston | Chief Financial Officer | MIXED | — | — |
| 2026-08-18 | Karen L. Zaderej | Director | Buy | — | — |
| 2026-07-14 | Jay S. Duker | President and CEO | MIXED | — | — |
| 2026-07-02 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | — |
| 2026-05-27 | George Elston | Chief Financial Officer | MIXED | — | — |
| 2026-04-20 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | — |
| 2026-03-24 | Jay S. Duker | President and CEO | J | — | — |
| 2026-03-16 | Jay S. Duker | President and CEO | Buy | — | — |
| 2026-03-06 | George Elston | Chief Financial Officer | G | — | — |
| 2026-03-05 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | — |
| 2026-02-18 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | — |
| 2026-01-07 | Nancy Lurker | Director | M | — | — |
| 2026-01-07 | Jay S. Duker | President and CEO | MIXED | — | — |
| 2026-01-07 | George Elston | Chief Financial Officer | MIXED | — | — |
| 2026-01-07 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | — |
| 2026-01-06 | John B. Landis | Director | A | — | — |
| 2026-01-06 | Reginald J. Sanders | Director | A | — | — |
| 2026-01-06 | Fred Hassan | Director | A | — | — |
| 2026-01-06 | GORAN ANDO | Director | A | — | — |
| 2026-01-06 | WENDY F DICICCO | Director | A | — | — |
| 2026-01-06 | Nancy Lurker | Director | M | — | — |
| 2026-01-06 | Stuart Duty | Director | A | — | — |
| 2026-01-06 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | — |
| 2026-01-06 | Jay S. Duker | President and CEO | MIXED | — | — |
| 2026-01-06 | Karen L. Zaderej | Director | A | — | — |
| 2026-01-06 | George Elston | Chief Financial Officer | MIXED | — | — |
| 2025-12-23 | George Elston | Chief Financial Officer | G | — | — |
| 2025-12-08 | Bihua Chen | — | Sell | — | — |
| 2025-12-05 | Nancy Lurker | Director | Sell | — | — |
| 2025-12-01 | Nancy Lurker | Director | Sell | — | — |
| 2025-11-12 | Ramiro Ribeiro | Chief Medical Officer | Sell | — | — |
| 2025-09-22 | George Elston | Chief Financial Officer | G | — | — |
| 2025-07-11 | Karen L. Zaderej | Director | M | — | — |
| 2025-07-11 | Jay S. Duker | President and CEO | MIXED | — | — |
| 2025-07-11 | Nancy Lurker | Director | M | — | — |
| 2025-07-02 | Nancy Lurker | Director | G | — | — |
| 2025-06-25 | Jay S. Duker | President and CEO | J | — | — |
| 2025-05-27 | George Elston | Chief Financial Officer | MIXED | — | — |
| 2025-05-19 | Karen L. Zaderej | Director | Buy | — | — |
| 2025-05-15 | Karen L. Zaderej | Director | Buy | — | — |
| 2025-03-20 | Jay S. Duker | President and CEO | J | — | — |
| 2025-02-11 | Jay S. Duker | President and CEO | MIXED | — | — |
| 2025-02-11 | George Elston | Chief Financial Officer | M | — | — |
| 2025-02-11 | Nancy Lurker | Director | M | — | — |
| 2025-01-08 | Reginald J. Sanders | Director | A | — | — |
| 2025-01-07 | GORAN ANDO | Director | A | — | — |
| 2025-01-07 | Stuart Duty | Director | A | — | — |
| 2025-01-07 | WENDY F DICICCO | Director | A | — | — |
| 2025-01-07 | George Elston | Chief Financial Officer | MIXED | — | — |
| 2025-01-07 | Jay S. Duker | President and CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,265,000 | — |
| — | 10%+ Owner | 7,288,479 | — |
| — | 10%+ Owner | 5,094,078 | — |
| — | 10%+ Owner | 3,510,921 | — |
| — | 10%+ Owner | 3,490,921 | — |
| — | 10%+ Owner | 3,490,921 | — |
| — | Director | 421,235 | — |
| — | President and CEO | 195,084 | — |
| — | Chief Financial Officer | 121,691 | — |
| — | Director | 100,221 | — |
| — | Director | 100,221 | — |
| — | Chief Medical Officer | 74,176 | — |
| — | Director | 49,100 | — |
| — | SVP & Chief Commercial Officer | 48,572 | — |
| — | Director | 21,400 | — |
| — | Director | 20,008 | — |
| — | Chief Corp Dev.&Strat. Officer | 13,662 | — |
| — | Director | 13,150 | — |
| — | Director | 11,917 | — |
| — | Director | 9,967 | — |
| — | See Remarks | 9,200 | — |
| — | Director | 8,016 | — |
| — | Director | 4,000 | — |
| — | Director | 1,850 | — |
| — | Director | 1,250 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EYPT quote page; the site-wide leaderboard is on the insider transactions hub.